Juventas
Juventas
Team
About Us > Team

Rahul Aras, President and CEORahul Aras, Ph.D.
(President and Chief Executive Officer)
is the founding CEO for Juventas. He is also a co-founder of SironRX Therapeutics, a company focused on novel regenerative therapies in the dermal and cosmetic fields. He has raised more than $35 million in venture capital and grant funding to transition both companies from concept into mid-stage clinical trials. Prior to Juventas, Rahul was the Director of Life Science Commercialization at Cleveland Clinic Innovations (CCI) where he is managed commercialization of all biotechnology and pharmaceutical related technologies. He has extensive experience negotiating licensing deals and strategic partnerships ranging from top 10 pharmaceutical companies to newly formed start-ups. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University. He has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals.

Mark PennMarc Penn, M.D., Ph.D.
(Founder and Chief Medical Officer)
is the Director of Research at the Summa Cardiovascular Institute in Akron, Ohio and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University where he leads the Skirball Laboratory for Cardiovascular Cellular Therapeutics. Dr. Penn was a staff cardiologist at the Cleveland Clinic from 2000 – 2011 where he served as the Director of the Coronary Intensive Care Unit, Director of the Experimental Animal Laboratory, Director of the Bakken Heart-Brain Institute, and the first Director of the Center for Cardiovascular Cell Therapy. He is a serial entrepreneur listed on more than 50 patents and patent applications and has contributed to the formation of multiple companies in the device, diagnostic and therapeutic spaces. Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University completing a Ph.D. in Biomedical Engineering in 1989 and Doctor of Medicine in 1994.

Joe PastoreJoseph Pastore, Ph.D.
(Vice President, Product Development)
leads Juventas' product development. He joined Juventas after working with Guidant Corporation (acquired by Boston Scientific) where he was a key member of the Emerging Therapies Division. Joe was responsible for translating novel cardiac therapies from concept to clinic. He managed pre-clinical, first-in-man, and Phase 2 clinical trials, and worked cross-functionally with business development, marketing, reimbursement and regulatory teams to build and execute development strategies for early stage products. An inventor on more than 40 issued and pending patents, he has experience with strategic patent writing and portfolio development. He was recognized with awards for 2003 CRM Patent of the Year and a President's Award (granted to the top 1% of the company).


Paul ResnickPaul Resnick, M.D., M.B.A.
(Vice President, Business Development)
leads Juventas' business and commercial development. Prior to Juventas, Dr. Resnick led business development for Intellikine, culminating in its acquisition by Takeda Pharmaceuticals. He previously held roles at Pfizer, Rinat Neuroscience (acquired by Pfizer), InterMune, and Roche and also practiced medicine. Dr. Resnick's professional experience includes product and business development with solid performance leading and executing business strategy resulting in transforming collaborations. Dr. Resnick earned a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Doctor of Medicine from the Medical College of Wisconsin.